No summary available.

Fresenius Medical Care (FMS) has released an update. Fresenius Medical Care AG, a company specializing in medical care products and services includ…

Fresenius Medical Care CEO Helen Giza comments on the firm''s second-quarter earning results.

Organic revenue growth of +2.3% supported by both segments Care Delivery and Care Enablement Operating income1 and operating income margin1 increase driven by Care Enablement Additional FME25 savings of EUR 57 million achieved and on track to reach the upper end of the full year savings…

Fresenius Medical Care reports Q2 2024 growth: 2.3% organic revenue increase, 19% operating income boost, and improved margins. Learn how strategic initiatives are driving the company''s turnaround and financial performance.

Fresenius Medical Care (FMS) has released an update. Fresenius Medical Care has reported progress in its financial performance for the second quart…

BAD HOMBURG, Germany (AP) — BAD HOMBURG, Germany (AP) — Fresenius Medical Care AG (FMS) on Tuesday reported second-quarter profit…

We predict a promising future for Fresenius Medical despite volatility, citing revenue growth, cost savings, and market leadership. See why FMCQF stock is a buy.

The U.S. Federal Trade Commission (FTC) is investigating healthcare providers DaVita and Fresenius Medical Care over allegations that the companies have been illegally thwarting smaller competitors, Politico reported on Saturday, citing three people familiar with the matter.

(Albany, USA) The Opioid Kappa Receptor Agonists market size is anticipated to grow in the upcoming years, largely driven by heightened R&D endeavors across the 7MM. Furthermore, the competitive landscape remains relatively sparse, indicating that the regulatory approval process is